One of our Directors, David Heal, will be participating in the 63rd Annual Meeting of the American College of Neuropsychopharmacology (ACNP), to be held at the JW Marriott Desert Ridge Resort & Spa, Phoenix, Arizona, USA, 8th-11th December 2024.
If you would like to see David at the ACNP to learn more about our services and research interests please get in touch or visit the following posters.
M215 Pharmacological Characterization of Centanafadine – Potential Implications for Efficacy and Safety in ADHD and Comorbid Psychiatric Disorders
David Heal¹,², Sharon Smith¹, Jane Gosden¹, Reem Elbekai³
¹DevelRx Ltd, BioCity, Nottingham, UK; ²Department of Life Sciences, University of Bath, Bath, UK; ³Otsuka Pharmaceutical Development & Commercialization, Inc, Rockville, Maryland, USA.
Poster Session I. Monday 9th December. 5.00-7.00 pm. Grand Canyon.
W228 New insights from electrophysiological and immunofluorescence experiments on the integration of kappa and mu opioid receptor signaling in the paraventricular thalamus
Eloise Kuijer¹,², Sarah Bailey¹, Sharon Smith³, Sue Wonnacott¹, Chris Bailey¹, David Heal¹,³
¹Department of Life Sciences, University of Bath, Bath, BA2 7AY, UK. ²Section of Sensory Science and Metabolism & Unit on Synaptic Modulation and Integration, National Institutes of Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland, USA. ³DevelRx Ltd, BioCity, Nottingham, NG1 1GF, UK.
Poster Session III. Wednesday 11th December. 5.00-7.00 pm. Grand Canyon.